

320. **Moliterno DJ.** The Year of Special Anniversaries: Tin, Crystal, Silver and Ruby. *JACC Cardiovascular Interventions* 2017;10:2587-2588. PMID: 29268892
321. Guimarães PO, Leonardi S, Huang Z, Wallentin L, Van de Werf F, Aylward PE, Held C, Harrington RA, **Moliterno DJ**, Armstrong PW, White HD, Alexander KP, Lopes RD, Mahaffey KW, Tricoci P, Clinical Features and Outcomes of Patients with Type 2 Myocardial Infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) Trial. *American Heart Journal* 2018;196:28-35. PMID: 29421012
322. Misumida N, **Moliterno DJ.** Hybrid coronary revascularization: Time for a new comparator? *Catheter Cardiovascular Interventions* 2018;91:213-214. PMID: 29405596
323. **Moliterno DJ.** The Top Papers of 2017: By Subsequent Citations and Online Views and Downloads. *JACC Cardiovascular Interventions* 2018;11:325-327. PMID: 29413251
324. **Moliterno DJ.** The Top Papers of 2017: Editor's Pick. *JACC Cardiovascular Interventions* 2018;11:513-515. PMID: 29519391
325. **Moliterno DJ.** State-of-the-Art Papers: Gemstones. *JACC Cardiovascular Interventions* 2018;11:613-614. PMID: 29566810
326. Rymer JA, Tempelhof MW, Clare RM, Pieper KS, Granger CB, Van de Werf F, **Moliterno DJ**, Harrington RA, White HD, Armstrong PW, Lopes RD, Mahaffey KW, Newby LK. Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction. *American Heart Journal* 2018;201:103-110. PMID: 29910048
327. Baber U, Li SX, Pinnelas R, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, **Moliterno DJ**, Colombo A, Mehran R. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). *Circulation Cardiovascular Interventions* 2018;11:e006144. PMID: 29870385
328. **Moliterno DJ.** Images in Intervention: Icons. *JACC Cardiovascular Interventions* 2018;11:1018-1019. PMID: 29798769
329. Tricoci P, Newby LK, Clare RM, Leonardi S, Gibson CM, Giugliano RP, Armstrong PW, Van de Werf F, Montalescot G, **Moliterno DJ**, Held C, Aylward PE, Wallentin L, Harrington RA, Braunwald E, Mahaffey KW, White HD. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. *JACC Cardiovascular Interventions*.2018;11:856-864. PMID: 29747915
330. Tricoci P, Neely M, Whitley MJ, Edelstein LC, Simon LM, Shaw C, Fortina P, **Moliterno DJ**, Armstrong PW, Aylward P, White H, Van de Werf F, Jennings LK, Wallentin L, Held C, Harrington RA, Mahaffey KW, Bray PF. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. *Blood Cells Molecules and Diseases* 2018;72:37-43. PMID: 30055940

331. **Moliterno DJ**. Year 1: A Short Look Back and a Long Look Forward. *JACC Cardiovascular Interventions* 2018;1:1793-1795. PMID: 30190073
332. Ungar L, Clare RM, Rodriguez F, Kolls BJ, Armstrong PW, Aylward P, Held C, **Moliterno DJ**, Strony J, Van de Werf F, Wallentin L, White HD, Tricoci P, Harrington RA, Mahaffey KW, Melloni C. Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. *Journal of the American Heart Association* 2018;7:e009609. PMID: 30526198
333. **Moliterno DJ**. Being a Great Reviewer: Remembering the “Why”. *JACC Cardiovascular Interventions* 2018;11:2130-2131. PMID: 30336820
334. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, **Moliterno DJ**, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP. *Circulation*. 2018;138:527-536. PMID:30571525
335. Sorrentino S, Giustino G, Baber U, Sartori S, Cohen DJ, Henry TD, Farhan S, Sharma M, Ariti C, Dangas G, Gibson M, Faggioni M, Krucoff MW, Aquino M, Chandrasekhar J, **Moliterno DJ**, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). *American Journal of Cardiology* 2018;122:1638-1646. PMID: 30270177
336. Schoos M, Power D, Baber U, Sartori S, Claessen B, Camaj A, Steg P, Ariti C, Weisz G, Witzenbichler B, Henry T, Cohen D, Antonucci D, Krucoff M, Hermiller J, Gibson C, Chieffo A, **Moliterno D**, Colombo A, Pocock S, Dangas G, Mehran R. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. *American Journal of Cardiology*. 2019 Mar 1;123(5):709-716. PMID:30612724
337. Moalem K, Baber U, Chandrasekhar J, Claessen BE, Sartori S, Aquino M, Dangas G, Iakovou I, Colombo A, Kini A, Gibson M, Krucoff M, Chieffo A, **Moliterno D**, Witzenbichler B, Pocock S, Mehran R. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. *Clinical Research Cardiology*. 2019 Jan 3 [Epub ahead of print] PMID: 30607496
338. Baber U, Leisman DE, Cohen DJ, Gibson CM, Henry TD, Dangas G, **Moliterno D**, Kini A, Krucoff M, Colombo A, Chieffo A, Sartori S, Witzenbichler B, Steg PG, Pocock SJ, Mehran R. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. *Circulation Cardiovascular Quality and Outcomes*. 2019;12:e004945. PMID:30606052
339. **Moliterno DJ**, Windecker S. Mitral Regurgitation and Evolving Transcatheter Treatments: Insights From the JACC Family of Journals. *Journal of the American College of Cardiology* 2019;73:1353-1357. PMID:30898211

1. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. *New England Journal of Medicine* 1997;337:1118-1123. PMID: 9340503
2. The Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial (EPISTENT) Investigators. Randomized placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein-IIb/IIIa blockade. *Lancet* 1998;352:87-92. PMID: 9672272
3. The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial. *Journal of the American College of Cardiology* 1998;32:2003-2010. PMID: 9857885
4. The NICE 4 Investigators. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 Trials. *Journal of Invasive Cardiology* 2000;12:E14-E18. PMID: 11156724
5. The Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction. *Circulation* 2000;101:2788-2794. PMID: 10859283
6. The SYMPHONY Investigators. Comparison of sibrifiban with aspirin, or both for secondary prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrifiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY). *Lancet* 2000;355:337-345. PMID: 10665552
7. The 2nd SYMPHONY Investigators. Randomized trial of aspirin, sibrifiban, or both for secondary prevention after acute coronary syndromes. *Circulation* 2001;103:1727-1733. PMID: 11282902
8. The NICE 4 Investigators. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. *Journal of Invasive Cardiology* 2001;13:272-278. PMID: 11287711
9. The PARAGON-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. *Circulation* 2002;105:316-321. PMID: 11804986
10. The PRIME Investigators. Multi-center, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion In Myocardial Infarction Evolution (PRIME) Trial. *American Heart Journal* 2002;143:95-105. PMID: 11773918
11. The APEX-AMI Investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. *Journal of the American Medical Association* 2007;297:43-51. PMID: 17200474
12. Cannon CP; STRIVE Scientific Committee. Updated Strategies and therapies for reducing ischemic and vascular events (STRIVE) unstable angina/non-ST-elevation myocardial infarction critical pathway toolkit. *Critical Pathways in Cardiology* 2008;7:43-81. PMID: 18458666

13. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. *Journal of the American Medical Association* 2008;299:1903-1913. PMID: 18430909
14. Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E; TRA2°P-TIMI 50 Investigators. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 Trial. *American Heart Journal* 2009;158:335-341.e3. PMID: 19699854
15. TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) Trial: study design and rationale. *American Heart Journal* 2009;158:327-334.e4. PMID: 19699853
16. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. *Journal of the American College of Cardiology*. 2010;55:2614-2662. PMID: 20513610
17. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS, Hlatky MA, Hodgson JM, Lauer MS, Miller JM, Morin RL, Mukherjee D, Poon M, Rubin GD, Schwartz RS, ACCF/ACRA/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation task force on expert consensus documents. *Journal of the American College of Cardiology* 2010;55:2663-2699. PMID: 20513611
18. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG, Ho VB, Jerosch-Herold M, Kramer CM, Manning WJ, Patel M, Pohost GM, Stillman AE, White RD, Woodard PK, ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation task force on consensus documents. *Circulation* 2010;121:2462-2508. PMID: 20479157
19. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS, Hlatky MA, Hodgson JM, Lauer MS, Miller JM, Morin RL, Mukherjee D, Poon M, Rubin GD, Schwartz RS, ACCF/ACRA/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomographic angiography: a report of the American College of Cardiology Foundation task force on expert consensus documents. *Circulation*. 2010;121:2509-2543. PMID: 20479158
20. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forcica MA, Frishman WH, Jaigobin C, Kostis JB, Mancina G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Circulation*. 2011;123:2434-2506. PMID: 21518977

21. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. *The New England Journal of Medicine* 2012;366:1404-1413. PMID: 22443427
22. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial. Third universal definition of myocardial infarction. *European Heart Journal* 2012;33:2551-2567. PMID: 22922414

Publications – Web Sites

1. Tan WS, **Moliterno DJ**. Acute coronary syndromes: unstable angina in non-Q wave MI. www.healthstream.com
2. **Moliterno DJ**. Contributing author to ACC Cardio. www.acc.org
3. **Moliterno DJ**. Acute Reactions from the AHA, 2003. www.atherothrombosis.org
4. **Moliterno DJ**. Knowing (and applying) our ABCs—online commentary of Mukherjee D, et al. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. *Circulation* 2004;109:745-9. www.americanheart.org
5. **Moliterno DJ**. Platelet GP IIb/IIIa Inhibitors. www.interventionalfellowsinstitute.com
6. **Moliterno DJ**. Thrombosis. Chapter 24 in “ACCSAP-6” (Adult Clinical Cardiology Self-Assessment Program) edited by Lewis RP; co-edited by O’Gara P, Friesinger II GC, Hirsch GA; American College of Cardiology, 2007. www.cardiosource.com
7. **Moliterno DJ**, Sketch M, Popma, Mukherjee D. Chief Editor and author or co-author of 6 modules in: “CathSAP-3” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program), published by American College of Cardiology Foundation and Society for Cardiovascular Angiography and Interventions. www.cardiosource.com

Publications - Book Chapters

1. **Moliterno DJ**, Elliott JM, Topol EJ. Randomized trials of myocardial revascularization. In “Current Problems in Cardiology” edited by O'Rourke RA; Mosby-Year Book, Inc., Mar 1995;20(3):123-190. PMID: 7600846
2. **Moliterno DJ**, Topol EJ. Clinical evaluation of restenosis. Chapter 93 in “Atherosclerosis and Coronary Artery Disease” edited by Fuster V, Ross R, Topol EJ; Raven Press, New York, 1995, pp 1505-1526.
3. **Moliterno DJ**, Topol EJ. Restenosis following coronary intervention. Update 17 for “Textbook of Interventional Cardiology” edited by Topol EJ; W.B. Saunders Company, Philadelphia, 1995, pp 257-2722.
4. Nissen SE, Tuzcu EM, De Franco AC, **Moliterno DJ**. Evaluation of stenosis severity: quantitative angiography, coronary flow reserve, and intravascular ultrasound. In “Strategic Approaches in Coronary Intervention” edited by Ellis SG, Holmes DA. Williams & Wilkins, Baltimore, 1995, pp 207-234.
5. **Moliterno DJ**, Topol EJ. Percutaneous versus surgical coronary revascularization. A summary of the RITA, CABRI, GABI, EAST, and BARI Trials. Update 23 for “Textbook of Interventional Cardiology” edited by Topol EJ; W. B. Saunders Company, Philadelphia, 1996, pp 335-344.
6. **Moliterno DJ**, Topol EJ. Thrombolysis in acute myocardial infarction. In “Cardiovascular Drug Therapy” edited by Mezznerli FH; W. B. Saunders Company, Philadelphia, 1996, pp 1430-1442.
7. Nissen SE, Tuzcu EM, De Franco AC, **Moliterno DJ**. Intravascular ultrasound assessments in coronary interventions. In “Handbook of Cardiovascular Interventions” edited by Sigwart U; Churchill Livingstone, New York, 1996.
8. Granger CJ, **Moliterno DJ**. Bedside anticoagulant testing. In “Acute Coronary Syndromes” edited by Topol EJ; Marcel Dekker, New York, 1998, pp 385-403.
9. Miller JM, Ohman EM, **Moliterno DJ**, Califf RM. Clinical evaluation of restenosis. In “Textbook of Interventional Cardiology” 3rd ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 1998, pp 379-415.
10. **Moliterno DJ**, Cohen M. Unstable angina. In “Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology” edited by Verstraete M, Fuster V, Topol EJ; Lippincott-Raven Publishers, Philadelphia, 1998, pp 439-460.
11. **Moliterno DJ**, Granger CB. Differences between unstable angina and myocardial infarction: the pathophysiologic and clinical spectrum. In “Acute Coronary Syndromes” edited by Topol EJ; Marcel Dekker, New York, 1998, pp 67-103.
12. **Moliterno DJ**, Topol EJ. Restenosis: epidemiology and treatment. In “Comprehensive Cardiovascular Medicine” edited by Topol EJ; Lippincott-Raven Publishers, Philadelphia, 1998, pp 2397-2432.
13. **Moliterno DJ**, Topol EJ. Restenosis: epidemiology and treatment. In “Textbook of Cardiovascular Medicine” edited by Topol EJ; Lippincott-Raven Publishers, Philadelphia, 1998, pp 2065-2100.

14. Steinhubl SR, **Moliterno DJ**. Antiplatelet and anticoagulant therapy in the prevention of ischemic heart disease. In "Preventative Cardiology" edited by Robinson R; Futura Publishing Co. Inc., Armonk, NY, 1998, pp 355-382.
15. **Moliterno DJ**. Anticoagulants in the treatment of acute coronary syndromes. In "Textbook of Interventional Cardiology" 3rd ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 1999, pp 25-51.
16. **Moliterno DJ**, White HD. Unstable angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS. In "Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease" edited by Lincoff AM, Topol EJ. Humana Press, Inc., Totowa, New Jersey 1999, pp 201-227.
17. Granger CJ, **Moliterno DJ**. Bedside anticoagulant testing. In "Acute Coronary Syndromes" 2nd ed. edited by Topol EJ; Marcel Dekker, New York, 2000, pp 541-562.
18. Kapadia SR, **Moliterno DJ**. Section II editors: Chronic ischemic syndromes. In "Manual of Cardiovascular Medicine" edited by Marso SP, Griffin BP, Topol EJ; Lippincott Williams & Wilkins, New York, 2000, pp 69-96.
19. **Moliterno DJ**. Anticoagulants. In "CathSAP II" edited by Nissen SE; American College of Cardiology; Bethesda, 2000, pp 23-30.
20. **Moliterno DJ**. Care after myocardial infarction. Section in "Conn's Current Therapy 2000" edited by RE Rakel; W.B. Saunders Co., Philadelphia, 2000, pp 328-333.
21. **Moliterno DJ**, Granger CB. Differences between unstable angina and myocardial infarction: The Pathophysiologic and Clinical Spectrum. In "Acute Coronary Syndromes" 2nd ed. edited by Topol EJ; Marcel Dekker, New York, NY, 2000, pp 135-172.
22. Mukherjee DB, **Moliterno DJ**. Bedside platelet monitoring. In "Acute Coronary Syndromes" 2nd ed. edited by Topol EJ; Marcel Dekker, New York, 2000, pp 563-597.
23. Chan AW, **Moliterno DJ**. Restenosis: the clinical issues. In "Textbook of Interventional Cardiology" 4th ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 2002, pp 415-453.
24. **Moliterno DJ**, Topol EJ. Restenosis: epidemiology and treatment. In "Textbook of Cardiovascular Medicine" 2nd ed. edited by Topol EJ; Williams & Wilkins Publishers, Philadelphia, 2002, pp 1715-1750.
25. **Moliterno DJ**. Anticoagulants and their use in acute coronary syndromes and coronary interventions. In "Textbook of Interventional Cardiology" 4th ed. edited by Topol EJ; W.B. Saunders Co., Philadelphia, 2003, pp 33-64.
26. **Moliterno DJ**. Unstable angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS. In "Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease" 2nd ed. edited by Lincoff AM, Topol EJ. Humana Press Inc., Totowa, NJ, 2003, pp 233-262.
27. Chan AW, **Moliterno DJ**. Clinical evaluation of restenosis. In "Atherothrombosis and Coronary Artery Disease" 2nd ed. edited Fuster V, Topol EJ, Nabel EG; Raven Press, New York, 2004.

63. Wiisanen ME, **Moliterno DJ**. Interrelationship of Thrombin and Platelets: The Protease Activated Receptor-1. Chapter 7 in “Therapeutic Advances in Thrombosis, 2nd edition.” edited by **Moliterno DJ**, Kristensen SD, De Caterina R, Wiley-Blackwell, London, 2012, pp 71-86.
64. **Moliterno DJ**. Hemostasis, Platelet Biology, and the Coagulation Cascade. Chapter 1.3 in “CathSAP-4” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation, 2012
65. Anaya P, **Moliterno DJ**. Hypercoaguable Disorders. Chapter 2.4 in “CathSAP-4” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation, 2012
66. **Moliterno DJ**. Heparin-Induced Thrombocytopenia. Chapter 6.6 in “CathSAP-4” (Cardiac Catheterization and Interventional Cardiology Self-Assessment Program) edited by **Moliterno DJ**, et al. American College of Cardiology Foundation, 2012
67. Macaulay TE, **Moliterno DJ**. Vasopressors, vasodilators, and antithrombotics in the catheterization laboratory. Chapter 7 in “Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease” edited by Mukherjee D, Bates E, Roffi M, Lange RA, **Moliterno DJ**; Informa Healthcare, London, 2018, pp 71-88.
68. **Moliterno DJ**, Macaulay TE. Antiplatelet, Antithrombotic, and Thrombolytic Agents. Chapter 5 in “Interventional Cardiology 1133 Questions: An Interventional Cardiology Board Review, 3rd Edition” edited by Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Wolters Kluwer, New York, 2019, pp 23-36.
69. Dunn SP, **Moliterno DJ**. Antiarrhythmics, Sedatives, and Lipid-lowering Agents. Chapter 7 in “Interventional Cardiology 1133 Questions: An Interventional Cardiology Board Review, 3rd Edition” edited by Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Wolters Kluwer, New York, 2019, pp 68-75.
70. Macaulay TE, Moliterno DJ. Inotropes, Vasopressors, and Vasodilators. Chapter 8 in “Interventional Cardiology 1133 Questions: An Interventional Cardiology Board Review, 3rd Edition” edited by Mukherjee D, Lange RA, Chatterjee S, Cho L, **Moliterno DJ**. Wolters Kluwer, New York, 2019, pp 76-83.

